The embattled blood-diagnostics firm had $200 million of cash on hand at the end of 2016, people familiar with the matter said, less than a quarter of the funding it raised from investors and partners.
from WSJ.com: US Business http://ift.tt/2ln0sv7
via IFTTT
No comments:
Post a Comment